VCNX VACCINEX, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1205922 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.4%
TTM net income YoY8.0%
TTM EPS YoY79.7%
Revenue 3-yr CAGR-12.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,117.3%
Net margin-3,100.5%
FCF margin-2,696.8%
EBITDA margin-3,101.8%
Returns
ROE—
ROA-598.5%
ROIC (approx.)—
Asset turnover0.19x
Leverage & solvency
Liabilities / assets195.8%
Debt / equity—
Current ratio0.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-78.6%
Payout ratio—
Capex / revenue3.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $601,000 | $570,000 |
| R&D expense | $12.54M | $16.57M |
| SG&A expense | $6.79M | $6.88M |
| Operating income | -$18.73M | -$22.89M |
| Interest expense | $2,000 | $1,000 |
| Pretax income | -$18.63M | -$20.25M |
| Income tax | $0 | $0 |
| Net income | -$18.63M | -$20.25M |
| EBITDA | -$18.64M | -$22.77M |
| EPS (basic) | -8.88 | -43.68 |
| EPS (diluted) | -8.88 | -43.68 |
| Weighted avg. shares (diluted) | 2.10M | 463,653 |
| Balance sheet | ||
| Cash & equivalents | $1.11M | $1.53M |
| Receivables | $838,000 | $961,000 |
| Current assets | $2.53M | $3.35M |
| PP&E, net | $65,000 | $136,000 |
| Total assets | $2.60M | $3.63M |
| Current liabilities | $5.08M | $5.92M |
| Short-term debt | $25,000 | $75,000 |
| Long-term debt | $0 | $26,000 |
| Total debt | $25,000 | $101,000 |
| Total liabilities | $5.08M | $5.94M |
| Shareholders' equity | -$2.49M | -$2.31M |
| Net debt | -$1.08M | -$1.43M |
| Shares outstanding | 2.68M | 892,617 |
| Cash flow statement | ||
| Operating cash flow | -$16.19M | -$21.38M |
| Capital expenditure | $22,000 | $67,000 |
| Free cash flow | -$16.21M | -$21.45M |
| Investing cash flow | -$22,000 | -$67,000 |
| Financing cash flow | $15.78M | $16.59M |
| Depreciation & amortization | $94,000 | $119,000 |
| Stock-based compensation | $341,000 | $474,000 |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.